ARCHIVES

Sanofi: Zaltrap Price Reflects Competing Drugs In Second-Line Metastatic Colon Cancer

This article is from The Cancer Letter archive.

Vol. 38 No. 41 | November 1, 2012

Download PDF Visit The Full Archive

Related Articles

HHS Carcinogen Guidelines For Labs Could Apply To Other

May 30, 1980

Bills Introduced On Breast Cancer Screening, DES, Cigarette Tax Hike

January 30, 1987

Benefits of Mammography Outweigh Harms In Women with Increased Risk, Starting at Age 40

April 27, 2012

Drug Shortages Reach All-Time High—Ben Venue Exit Will Make Problem Worse

October 11, 2013

NCAB Can’t Decide Fate of Women’s Health Trial, Forces It Back Into Lap of DCPC Scientific Advisors

October 2, 1987

NCI-Approved Clinical Trials Listed For May 2001

June 29, 2001